Cardlytics, Inc. (CDLX) [Rocket]

Overview

Cardlytics, Inc. (CDLX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/03/2023	4	Lynton Nicholas Hollmeyer (Chief Legal & Privacy Officer) has filed a Form 4 on Cardlytics, Inc.
10/03/2023	4	Temsamani Karim Saad (CEO) has filed a Form 4 on Cardlytics, Inc.
10/02/2023	144	Form 144 - Report of proposed sale of securities:
10/02/2023	144	Form 144 - Report of proposed sale of securities:
08/14/2023	4	DeSieno Alexis (CFO) has filed a Form 4 on Cardlytics, Inc.
08/14/2023	3	DeSieno Alexis (CFO) has filed a Form 3 on Cardlytics, Inc.
08/09/2023	4	Lynton Nicholas Hollmeyer (Chief Legal & Privacy Officer) has filed a Form 4 on Cardlytics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	277.2	258.8	186.9	210.4	150.7	130.4	112.8	77.6
Revenue growth	7.1%	38.5%	-11.2%	39.6%	15.6%	15.6%	45.3%
Cost of goods sold	57.7	164.2	122.9	131.0	96.0	80.3	98.3	52.5
Gross profit	219.4	94.6	64.0	79.5	54.7	50.1	14.5	25.1
Gross margin	79.2%	36.5%	34.2%	37.8%	36.3%	38.4%	12.9%	32.4%
Sales and marketing	74.7	66.0	45.3	43.8	41.9	31.9	31.3	32.8
Research and development	54.4	38.1	17.5	11.7	16.2	12.2	13.9	11.6
General and administrative	81.4	66.2	46.5	36.7	34.2	20.1	21.4	18.2
EBIT	-135.5	-95.9	-53.2	-17.3	-40.9	-17.1	-56.2	-39.6
EBIT margin	-48.9%	-37.1%	-28.5%	-8.2%	-27.2%	-13.1%	-49.8%	-51.1%
Pre-tax income	-466.7	-136.4	-55.4	-17.1	-53.0	-19.6	-75.7	-40.6
Income taxes	-1.4	-7.9	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.3%	5.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-465.3	-128.6	-55.4	-17.1	-53.2	-25.4	-76.7	0.0
Net margin	-167.9%	-49.7%	-29.7%	-8.1%	-35.3%	-19.5%	-68.0%	-0.1%

Diluted EPS	($13.92)	($3.99)	($2.04)	($0.72)	($2.79)	($7.86)	($32.48)	($19.91)
Shares outstanding (diluted)	33.4	32.2	27.2	23.7	19.1	3.2	2.4	0.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.